NPM: A new player in prostate canter?;NPM: Un nouvel acteur dans le cancer de la prostate?

Medecine/Sciences

Volumn 25, Issue 1, 2009, Pages 19-21

  Beaudoin, Claude ^a   Maquaire, Sabrina ^a   Léotoing, Laurent ^b   Allemand, Jérôme ^a   Lours Calet, Corinne ^a   Veyssière, Georges ^a   Manin, Michèle ^a   Morel, Laurent ^a  

^a INSERM   (France)

^b INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58849086011     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200925119     Document Type: Short Survey

References (15)

1. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1991 ; 43 : 209-23.
2. Russell PJ, Benette S, Stricker P. Growth factor involvment in the progression of prostate cancer. Clin Chem 1998 ; 44 : 705-23.
3. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocrinol Rev 2007 ; 28 : 778-808.
4. Kaarbo M, Klakk TI, Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays 2007 ; 29 : 1227-38.
5. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005 ; 437 : 147-53.
6. Grisendi S, Mecucci C, Falini B, et al. Nucleophosmin and cancer. Nat Rev Cancer 2006 ; 6 : 493-505.
7. Leotoing L, Meunier L, Manin M, et al. Influence of nucleophosmin/B23 on DNA binding and transcriptional activity of the androgen receptor in prostate cancer cell. Oncogene 2008 ; 27 : 2858-67.
8. Swaminathan V, Kishore AH, Febitha KK, et al. Human histone chaperone nucleophosmin enhances acetylation-dependent chromatin transcription. Mol Cell Biol 2005 ; 25 : 7534-45.
9. Fu M, Wang C, Wang J, et al. Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans- repression function. Mol Cell Biol 2002 ; 22 : 3373-88.
10. Jia L, Shen HC, Wantroba M, et al. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol 2006 ; 26 : 7331-41.
11. Wissmann M, Yin N, Muller JM, et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 2007 ; 9 : 347-53.
12. Metzger E, Yin N, Wissmann M, et al. Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol 2008 ; 10 : 53-60.
13. Labrie F, Cusan L, Gomez JL, et al. De la biologie à la clinique : le décès dû au cancer de la prostate peutil maintenant être une exception ? Med Sci (Paris) 2003 ; 19 : 910-9.
14. Cussenot O, Cancel-Tassin G. Facteurs de risque génétiques pour le cancer de lo prostate. Med Sci (Paris) 2004 ; 20 : 562-8.
15. Ray-Gallet D, Gérard A, Polo S, Almouzni G. Variations sur le thème du «code histone». Med Sci (Paris) 2005 ; 21 : 384-9.